SLC West Liu Aff
| Tournament | Round | Opponent | Judge | Cites | Round Report | Open Source | Edit/Delete |
|---|---|---|---|---|---|---|---|
| Contact Info | 1 | none | none |
|
| ||
| Jack Howe | 2 | Joey Antonelli | Joseph Barquin |
|
|
| |
| Jack Howe | 5 | Christopher Robertson | Benjamin Cortez |
|
|
| |
| Jack Howe | 4 | Anika Akshantala | Saketh Kotapati |
|
|
| |
| Meadows | 2 | Liam Nyberg | Asher Towner |
|
|
| |
| Meadows | 3 | Shaye Lee | Leah Villanueva |
|
|
| |
| Strake | 2 | Kelvin Meng | Robert Yang |
|
|
|
| Tournament | Round | Report |
|---|---|---|
| Jack Howe | 2 | Opponent: Joey Antonelli | Judge: Joseph Barquin 1AC - evergreening |
| Jack Howe | 5 | Opponent: Christopher Robertson | Judge: Benjamin Cortez 1AC - evergreening |
| Jack Howe | 4 | Opponent: Anika Akshantala | Judge: Saketh Kotapati 1AC - evergreening disclosure |
| Meadows | 2 | Opponent: Liam Nyberg | Judge: Asher Towner 1AC - evergreening V2 |
| Meadows | 3 | Opponent: Shaye Lee | Judge: Leah Villanueva 1AC - eg v2 |
| Strake | 2 | Opponent: Kelvin Meng | Judge: Robert Yang 1AC - cap |
To modify or delete round reports, edit the associated round.
Cites
| Entry | Date |
|---|---|
0 - Contact InfoTournament: Contact Info | Round: 1 | Opponent: none | Judge: none | 9/20/21 |
0 - Organization NoteTournament: Contact Info | Round: 1 | Opponent: none | Judge: none | 9/20/21 |
1 - DisclosureTournament: Jack Howe | Round: 4 | Opponent: Anika Akshantala | Judge: Saketh Kotapati Interp: Debaters must open source or cite all broken constructive positions with highlighting from TOC bid tournaments on the 2021-2022 NDCA LD wiki after they read them in round.Violation: They don’t
Standards1~ Levels the playing field—Antonucci 05 ~Michael (Debate coach for Georgetown; former coach for Lexington High School); "~eDebate~ open source? resp to Morris"; December 8; http://www.ndtceda.com/pipermail/edebate/2005-December/064806.html ~ AND -cutter's work than send the KGB after specific counter-revolutionary teams. 2~ Evidence ethics—disclosure is the only way to verify ethically cut cards, 4 minutes is too short, ev ethics is part of being a good academic that’s a voterEducation—it’s the only takeaway from debateAccess—not everyone has a fair shot and equitable educationDrop the debater for norm settingNo RVI a~ debaters bait theory for RVI’s making LD worse b~ you don’t get a cookie for being fairCompeting interps Reasonability requires judge intervention | 10/30/21 |
2 - 1AC Evergreening V1Tournament: Jack Howe | Round: 2 | Opponent: Joey Antonelli | Judge: Joseph Barquin 1AC – Evergreening V2AdvantageInnovation low now – secondary patents gut the incentive and skyrocket price of Naloxone, HIV meds, insulin, and even basic allergy drugs – the only comprehensive studyAV 20 ("‘Evergreening’ Stunts Competition, Costs Consumers and Taxpayers." Arnold Ventures, Arnold Foundation, 24 Sept. 2020, www.arnoldventures.org/stories/evergreening-stunts-competition-costs-consumers-and-taxpayers/.)LK ~Accessed 8/23/2021~ AND billions of dollars while increasing the incentives for pharmaceutical companies to achieve breakthroughs." They’re endemic to the industry and 80 of patents were not for new drugs – their stats ignore the quality of the innovation which is nonexistantRobin 18 (Robin Feldman, May your drug price be evergreen, Journal of Law and the Biosciences, Volume 5, Issue 3, December 2018, Pages 590–647, https://doi.org/10.1093/jlb/lsy022 ~Robin Feldman, Hastings College of the Law, University of California~)LK ~Accessed 8/23/21~ AND exclusivity, but also other significant changes such as adding a use code.) Secondary patents are the root cause and less than 1/6 of revenues go to RandD – ignore their lies told by big pharmaRadhakrishnan 16 Priti Radhakrishnan 6-14-2016 "Pharma’s secret weapon to keep drug prices high" https://www.statnews.com/2016/06/14/secondary-patent-gilead-sovaldi-harvoni/ (Priti Radhakrishnan is cofounder and director of the Initiative for Medicines, Access and Knowledge (I-MAK), a US-based nonprofit group of scientists and lawyers working globally to get people lifesaving medicines. Before founding I-MAK, she worked as a health attorney in the US, Switzerland, and India.)Elmer LK ~RCT~ AND are unmerited and that unjustly prolong companies’ market power and prevent legitimate competition. Independently, it’s the root cause of AIDS backsliding – kills millions each yearFrontline AIDS ("How Patents Affect Access to Hiv Treatment." Frontline AIDS, 2 October 2019, frontlineaids.org/how-patents-affect-access-to-hiv-treatment/)LK ~Accessed 8/25/2021~ *pppy = per person per year AND put into practice we risk undermining the commitments made to the HIV response. We control uniqueness – innovation is low now and it solves disease, bioterror and antimicrobial resistance. The response to COVID is the exception, not the rule.Marjanovic and Feijao 20 (Marjanovic, Sonja and Carolina Feijao, Pharmaceutical Innovation for Infectious Disease Management: From Troubleshooting to Sustainable Models of Engagement. Santa Monica, CA: RAND Corporation, 2020. https://www.rand.org/pubs/perspectives/PEA407-1.html)//LK ~Accessed 8/30/31~ AND different types of infectious disease threats and phases in framing incentives and regulation. 3 Impacts:1~ Antimicrobial resistance triggers extinction.Srivatsa ’17 (Kadiyali; specialist in pediatric intensive and critical care medicine in the UK. Invented the bacterial identification tool ‘MAYA’; 1-12-2017; "Superbug Pandemics and How to Prevent Them", American Interest; https://www.the-american-interest.com/2017/01/12/superbug-pandemics-and-how-to-prevent-them/, Accessed: 8-31-2021; AU) AND most of the medical advances we have made over the past fifty years. 2~ Innovation is key to treat neglected tropical diseases – that revives global health diplomacyHotez 16, Peter J. Blue marble health: an innovative plan to fight diseases of the poor amid wealth. JHU Press, 2016. (Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology)Elmer LK ~RCT 9/15/2021~ AND , Burkina Faso, and Niger, as well as Nigeria ~11~. Solves hotspot escalationNang and Martin 17, Roberto N., and Keith Martin. "Global health diplomacy: A new strategic defense pillar." Military medicine 182.1-2 (2017): 1456-1460. (MC, Global Health Division, Uniformed Services University of the Health Sciences)Elmer AND the ability and authority to do so in the national and international interest. 3~ Bioweapons cause extinction – mathematically outweighs, even if they win mitigation.Millett and Snyder-Beattie ‘17. Millett, Ph.D., Senior Research Fellow, Future of Humanity Institute, University of Oxford; and Snyder-Beattie, M.S., Director of Research, Future of Humanity Institute, University of Oxford. 08-01-2017. "Existential Risk and Cost-Effective Biosecurity," Health Security, 15(4), PubMed AND still ought to invest more in preventing the most extreme possible biosecurity catastrophes. AdvocacyThus, the plan: the member nations of the World Trade Organization ought to reduce intellectual property protections for medicines by limiting drug innovators to one market exclusivity of their choice for their drug.Solves better than any counterplan – only the aff tackles incentivesFeldman 19 (Feldman, Robin. "Drug Patent Protection: It's Time for a 'One-and-Done' Approach." STAT, 11 Feb. 2019, www.statnews.com/2019/02/11/drug-patent-protection-one-done/. ~Robin Feldman is professor of law and director of the Institute for Innovation Law at UC Hastings College of the Law in San Francisco and author of "Drugs, Money, and Secret Handshakes" (Cambridge University Press, March 2019).~)LK ~Accessed 8/25/2021~ AND right now, the incentives for creating patent walls are just too great. Framing —- UtilThe standard is maximizing expecting well being.1~ Actor specificity—-A~ Aggregation – every policy benefits some and harms others, which also means side constraints freeze action.—-B~ No act-omission distinction – choosing to omit is an act itself – governments actively decide not to act so there is no omission2~ Util is a lexical pre-requisite to any other framework: Threats to life preclude the ability for moral actors to effectively utilize and act upon other moral theories since they are in a constant state of crisis – that inhibits the ideal moral conditions which other theories presuppose.3~ Extinction matters under any framework:—-A~ It precludes the possibility of any kind of moral value – we can’t confer value onto anything if we’re not alive.—-B~ Future generations means infinite magnitude – we have to look towards future lives tooUnderviewThe 1AC’s scholarship supplements resistance because it maps the supply lines and networks that create complex systems of power.Bryant 12 – Levi Bryant Professor of Philosophy at Collin College. In addition to working as a professor, Bryant has also served as a Lacanian psychoanalyst. He received his Ph.D. from Loyola University in Chicago, Illinois, where he originally studied 'disclosedness' with the Heidegger scholar Thomas Sheehan. Bryant later changed his dissertation topic to the transcendental empiricism of Gilles Deleuze. "War Machines and Military Logistics: Some Cards on the Table" 9/15/2012. IB AND , and communications networks, and so we can engage in effective terraformation. Root cause explanations of international politics don’t exist – methodological pluralism is necessary to reclaim IR as emancipatory praxis and avoid endless political violence.Bleiker ‘14 (6/17, Roland, Professor of International Relations at the University of Queensland, "International Theory Between Reification and Self-Reflective Critique," International Studies Review, Volume 16, Issue 2, pages 325–327) AND and complexity theory—links that could have been explored in more detail. | 9/20/21 |
2 - 1AC Evergreening V2Tournament: Jack Howe | Round: 4 | Opponent: Anika Akshantala | Judge: Saketh Kotapati AdvantageInnovation low now – secondary patents gut the incentive and skyrocket price of Naloxone, HIV meds, insulin, and even basic allergy drugs – the only comprehensive studyAV 20 ("‘Evergreening’ Stunts Competition, Costs Consumers and Taxpayers." Arnold Ventures, Arnold Foundation, 24 Sept. 2020, www.arnoldventures.org/stories/evergreening-stunts-competition-costs-consumers-and-taxpayers/.)LK ~Accessed 8/23/2021~ AND billions of dollars while increasing the incentives for pharmaceutical companies to achieve breakthroughs." They’re endemic to the industry and 80 of patents were not for new drugs – their stats ignore the quality of the innovation which is nonexistantRobin 18 (Robin Feldman, May your drug price be evergreen, Journal of Law and the Biosciences, Volume 5, Issue 3, December 2018, Pages 590–647, https://doi.org/10.1093/jlb/lsy022 ~Robin Feldman, Hastings College of the Law, University of California~)LK ~Accessed 8/23/21~ AND exclusivity, but also other significant changes such as adding a use code.) Secondary patents are the root cause and less than 1/6 of revenues go to RandD – ignore their lies told by big pharmaRadhakrishnan 16 Priti Radhakrishnan 6-14-2016 "Pharma’s secret weapon to keep drug prices high" https://www.statnews.com/2016/06/14/secondary-patent-gilead-sovaldi-harvoni/ (Priti Radhakrishnan is cofounder and director of the Initiative for Medicines, Access and Knowledge (I-MAK), a US-based nonprofit group of scientists and lawyers working globally to get people lifesaving medicines. Before founding I-MAK, she worked as a health attorney in the US, Switzerland, and India.)Elmer LK ~RCT~ AND are unmerited and that unjustly prolong companies’ market power and prevent legitimate competition. We control uniqueness – innovation is low now and it solves disease, bioterror and antimicrobial resistance. The response to COVID is the exception, not the rule.Marjanovic and Feijao 20 (Marjanovic, Sonja and Carolina Feijao, Pharmaceutical Innovation for Infectious Disease Management: From Troubleshooting to Sustainable Models of Engagement. Santa Monica, CA: RAND Corporation, 2020. https://www.rand.org/pubs/perspectives/PEA407-1.html)//LK ~Accessed 8/30/31~ AND different types of infectious disease threats and phases in framing incentives and regulation. 3 Impacts:1~ Antimicrobial resistance triggers extinction.Srivatsa ’17 (Kadiyali; specialist in pediatric intensive and critical care medicine in the UK. Invented the bacterial identification tool ‘MAYA’; 1-12-2017; "Superbug Pandemics and How to Prevent Them", American Interest; https://www.the-american-interest.com/2017/01/12/superbug-pandemics-and-how-to-prevent-them/, Accessed: 8-31-2021; AU) AND most of the medical advances we have made over the past fifty years. 2~ Innovation is key to treat neglected tropical diseases – that revives global health diplomacyHotez 16, Peter J. Blue marble health: an innovative plan to fight diseases of the poor amid wealth. JHU Press, 2016. (Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology)Elmer LK ~RCT 9/15/2021~ AND , Burkina Faso, and Niger, as well as Nigeria ~11~. Solves hotspot escalationNang and Martin 17, Roberto N., and Keith Martin. "Global health diplomacy: A new strategic defense pillar." Military medicine 182.1-2 (2017): 1456-1460. (MC, Global Health Division, Uniformed Services University of the Health Sciences)Elmer AND the ability and authority to do so in the national and international interest. 3~ Bioweapons cause extinction – mathematically outweighs, even if they win mitigation.Millett and Snyder-Beattie ‘17. Millett, Ph.D., Senior Research Fellow, Future of Humanity Institute, University of Oxford; and Snyder-Beattie, M.S., Director of Research, Future of Humanity Institute, University of Oxford. 08-01-2017. "Existential Risk and Cost-Effective Biosecurity," Health Security, 15(4), PubMed AND still ought to invest more in preventing the most extreme possible biosecurity catastrophes. AdvocacyThus, the plan: the member nations of the World Trade Organization ought to reduce intellectual property protections for medicines by limiting drug innovators to one market exclusivity of their choice for their drug.Solves better than any counterplan – only the aff tackles incentivesFeldman 19 (Feldman, Robin. "Drug Patent Protection: It's Time for a 'One-and-Done' Approach." STAT, 11 Feb. 2019, www.statnews.com/2019/02/11/drug-patent-protection-one-done/. ~Robin Feldman is professor of law and director of the Institute for Innovation Law at UC Hastings College of the Law in San Francisco and author of "Drugs, Money, and Secret Handshakes" (Cambridge University Press, March 2019).~)LK ~Accessed 8/25/2021~ AND right now, the incentives for creating patent walls are just too great. Framing —- UtilThe standard is maximizing expecting well being.1~ Actor specificity—-A~ Aggregation – every policy benefits some and harms others, which also means side constraints freeze action.—-B~ No act-omission distinction – choosing to omit is an act itself – governments actively decide not to act so there is no omission2~ Util is a lexical pre-requisite to any other framework: Threats to life preclude the ability for moral actors to effectively utilize and act upon other moral theories since they are in a constant state of crisis – that inhibits the ideal moral conditions which other theories presuppose.3~ Extinction matters under any framework:—-A~ It precludes the possibility of any kind of moral value – we can’t confer value onto anything if we’re not alive.—-B~ Future generations means infinite magnitude – we have to look towards future lives too~ 1AR theory underview –—-A~ AFF gets it because otherwise the neg can engage in infinite abuse, making debate impossible. No 2n theory – kills resolvability because judge has to intervene in weighing interp and 2ar counterinterp.—-B~ drop the debater – the short 1AR irreparably skewed from abuse on substance and time investment on theory.—-C~ no RVIs – the 6-minute 2nr can collapse to a short shell and get away with infinite 1nc abuse via sheer brute force and time spent on theory.—-D~ Use competing interps – 1AR interps aren’t bidirectional and the neg should have to defend their norm since they have more time.~ Yes Aff RVIs—-A~ I have a 4 minute 1AR to answer T or Theory which skews my time from other arguments. T bites out of a higher percentage of my rebuttal time.—-B~ No risk issue for the negative, you can go for it in the 2nr if I undercover but if I overallocate you can just kick it.~ Fairness is a voter – debate is a competitive activity and needs both debaters to be on an equal playing field argumentatively. | 10/30/21 |
Open Source
| Filename | Date | Uploaded By | Delete |
|---|---|---|---|
9/20/21 | mliu7051@gmailcom |
| |
10/30/21 | mliu7051@gmailcom |
|